FUM Futura Medical plc
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Futura Medical (LON: FUM)
›
Futura Medical (LON: FUM) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.2170 GBp on 19 November 2026, down 90.4% over 52 weeks. Its 52-week range is 0.1595 GBp to 2.350 GBp: the price is 90.8% below the high and 36.1% above the low.
Its market capitalisation is 3.22M GBP.
Futura Medical reports return on equity of -323.4%, an operating margin of -133.4% and revenue up 62.0% year over year.
It holds more cash than debt, a net cash position of 1.24M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.